{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:02:51Z","timestamp":1792425771767,"version":"4.5.0"},"reference-count":22,"publisher":"BMJ","issue":"9","funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["20FC1030"],"award-info":[{"award-number":["20FC1030"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the association between changes in anti-acetylcholine receptor antibody (AChR Ab) levels induced by immunosuppressive treatment and myasthenia gravis (MG) prognosis at 1-year post-treatment in patients with MG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included 53 consecutive AChR Ab-positive patients with MG whose AChR Ab levels were remeasured within 100 days of initiating immunosuppressive treatment (median remeasuring time post-treatment: 71 (55\u201384) days). The AChR Ab level reduction rate (RR-AChRAb, %\/day) adjusted for the time between treatment initiation, and AChR Ab level remeasurement was calculated as follows: (pretreatment\u2013post-treatment AChR Ab level)\/pretreatment AChR Ab level\/days between therapy initiation and AChR Ab level remeasurement \u00d7100. Participants were divided into two groups based on the cut-off value of RR-AChR Ab, determined using receiver operating characteristic analyses for achieving minimal manifestation (MM) or better status at 1-year postimmunosuppressive treatment. The Myasthenia Gravis Foundation of America postintervention status and MG activity of daily living (MG-ADL) score at 1-year post-treatment were compared between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The RR-AChRAb cut-off value was 0.64%\/day. The high RR-AChRAb group had a higher ratio of MM or better status (90% vs 65%, p=0.03) and lower MG-ADL score (median; 1 vs 2, p=0.04) than the low RR-AChRAb group. Kaplan-Meier analyses showed the early MM achievement in the high RR-AChRAb group (p=0.002, log-rank test).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>High RR-AChRAb is associated with a favourable outcome at 1-year post-treatment. AChR Ab remeasurement within 100 days of therapy may be useful for predicting AChR Ab-positive MG outcomes at 1-year post-treatment.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2020-325511","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T10:50:16Z","timestamp":1628851816000},"page":"963-968","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome"],"prefix":"10.1136","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-5419","authenticated-orcid":false,"given":"Yuta","family":"Kojima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-1863","authenticated-orcid":false,"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manato","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Akamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Himuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1169-8574","authenticated-orcid":false,"given":"Yu-ichi","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4716-8578","authenticated-orcid":false,"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"2021092308400888000_92.9.963.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05186-2"},{"key":"2021092308400888000_92.9.963.2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.43.7.601"},{"key":"2021092308400888000_92.9.963.3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.54.2.474","article-title":"Mechanism of block of nicotinic acetylcholine receptor channels by purified IgG from seropositive patients with myasthenia gravis","volume":"54","author":"Jahn","year":"2000","journal-title":"Neurology"},{"key":"2021092308400888000_92.9.963.4","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322640"},{"key":"2021092308400888000_92.9.963.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51301.x"},{"key":"2021092308400888000_92.9.963.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.7.3090"},{"key":"2021092308400888000_92.9.963.7","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.56.5.496"},{"key":"2021092308400888000_92.9.963.8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.28.3.266"},{"key":"2021092308400888000_92.9.963.9","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jca.21694","article-title":"Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status","volume":"34","author":"Usmani","year":"2019","journal-title":"J Clin Apher"},{"key":"2021092308400888000_92.9.963.10","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23944"},{"key":"2021092308400888000_92.9.963.11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: putting into practice","volume":"6","author":"Murai","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"key":"2021092308400888000_92.9.963.12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.16"},{"key":"2021092308400888000_92.9.963.13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487"},{"key":"2021092308400888000_92.9.963.14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/cen3.12091","article-title":"Clinical features and treatment status of adult myasthenia gravis in Japan","volume":"5","author":"Murai","year":"2014","journal-title":"Clin Exp Neuroimmunol"},{"key":"2021092308400888000_92.9.963.15","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj063"},{"key":"2021092308400888000_92.9.963.16","first-page":"33","article-title":"Antibody specificity in myasthenia gravis","volume":"25","author":"Vincent","year":"1988","journal-title":"Monogr Allergy"},{"key":"2021092308400888000_92.9.963.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51285.x"},{"key":"2021092308400888000_92.9.963.18","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/mus.25205","article-title":"Factors affecting outcome in myasthenia gravis","volume":"54","author":"Andersen","year":"2016","journal-title":"Muscle Nerve"},{"key":"2021092308400888000_92.9.963.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-016-0756-3","article-title":"Response to treatment of myasthenia gravis according to clinical subtype","volume":"16","author":"Akaishi","year":"2016","journal-title":"BMC Neurol"},{"key":"2021092308400888000_92.9.963.20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316625"},{"key":"2021092308400888000_92.9.963.21","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/mus.25397","article-title":"Early fast-acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa","year":"2017","journal-title":"Muscle Nerve"},{"key":"2021092308400888000_92.9.963.22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nyas.13544","article-title":"Rationale for the clinical guidelines for myasthenia gravis in Japan","volume":"1413","author":"Murai","year":"2018","journal-title":"Ann N Y Acad Sci"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2020-325511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T01:15:09Z","timestamp":1632446109000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2020-325511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,8,13]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/jnnp-2020-325511"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2020-325511","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]}}}